Acacia Pharma is a hospital pharmaceutical group focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer therapy. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and procedural sedation, and has three product candidates in its late-stage pipeline designed to meet those needs.
BARHEMSYS® is approved in the US for the treatment and prophylaxis of postoperative nausea & vomiting (PONV), either alone or in combination other antiemetics (February 2020). US launch is planned for 2H 2020.
Acacia Pharma’s latest opportunity, BYFAVO™, has been in-licensed from Cosmo Pharmaceuticals for the US market. BYFAVO is an ultra-short-acting and reversible intravenous sedative/anesthetic designed for use during invasive medical procedures, such as during colonoscopy and bronchoscopy with an NDA filed and a target review date of 5 July 2020.
The Group’s pipeline also includes APD403 for chemotherapy induced nausea & vomiting (CINV). APD403 is based on the selective dopamine antagonist amisulpride, the same active ingredient as in BARHEMSYS. It is being developed in both intravenous and oral form and has successfully completed Phase 2 testing in patients receiving highly emetogenic chemotherapy.
Acacia Pharma plans to commercialize its products directly in the US through its own commercial operations targeting anaesthesiologists and oncologists. Acacia Pharma intends to establish licensing and/or distribution agreements with selected pharmaceutical partners outside the US.
The Company’s management team and Board have extensive experience in the discovery, development and commercialization of hospital pharmaceutical products.
Acacia Pharma has offices in Cambridge, UK and Indianapolis, IN, USA, and is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.